Other equities research analysts have also recently issued reports about the company. HC Wainwright decreased their price target on Mersana Therapeutics from $24.00 to $19.00 in a report on Monday, May 9th. Zacks Investment Research raised Mersana Therapeutics from a hold rating to a buy rating and set a $4.00 price target on the stock in a report on Tuesday, May 3rd. Finally, SVB Leerink reduced their target price on Mersana Therapeutics from $25.00 to $16.00 and set an outperform rating on the stock in a report on Friday, February 18th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Mersana Therapeutics has a consensus rating of Buy and a consensus target price of $17.80.
NASDAQ MRSN opened at $2.98 on Tuesday. The company has a market capitalization of $289.03 million, a PE ratio of -1.20 and a beta of 2.37. The company has a debt-to-equity ratio of 0.18, a quick ratio of 3.97 and a current ratio of 4.28. The business’s fifty day moving average is $3.99 and its 200 day moving average is $5.41. Mersana Therapeutics has a fifty-two week low of $2.68 and a fifty-two week high of $15.34.
In related news, Director Andrew A. F. Hack acquired 598,086 shares of Mersana Therapeutics stock in a transaction on Tuesday, April 12th. The shares were bought at an average cost of $4.18 per share, with a total value of $2,499,999.48. Following the completion of the purchase, the director now directly owns 7,120,116 shares of the company’s stock, valued at approximately $29,762,084.88. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 5.30% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its stake in Mersana Therapeutics by 47.2% during the third quarter. Royal Bank of Canada now owns 6,941 shares of the company’s stock worth $66,000 after acquiring an additional 2,226 shares during the last quarter. Ensign Peak Advisors Inc bought a new stake in Mersana Therapeutics during the fourth quarter worth approximately $56,000. Point72 Hong Kong Ltd bought a new stake in Mersana Therapeutics during the fourth quarter worth approximately $57,000. Victory Capital Management Inc. bought a new stake in Mersana Therapeutics during the first quarter worth approximately $36,000. Finally, Teacher Retirement System of Texas purchased a new position in shares of Mersana Therapeutics during the fourth quarter valued at approximately $67,000. 92.74% of the stock is currently owned by institutional investors.
Mersana Therapeutics Company Profile (Get Rating)
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.
- Get a free copy of the StockNews.com research report on Mersana Therapeutics (MRSN)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Mersana Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mersana Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.